Roth Capital upgraded DepoMed Inc. (Nasdaq: DEPO) from a Neutral rating to a
Buy rating and lifted its price target from $13.50 to $25. The stock price soared $2.55 to close at $20.20.
DepoMed upgraded
January 16, 2015 at 18:16 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.